AC
Armistice Capital Portfolio holdings
AUM
$2.64B
This Quarter Return
+6.93%
1 Year Return
+0.99%
3 Year Return
+16.29%
5 Year Return
+18.04%
10 Year Return
+34.8%
AUM
$3.72B
AUM Growth
+$3.72B
(-6.4%)
Cap. Flow
-$740M
Cap. Flow
% of AUM
-19.91%
Top 10 Holdings %
Top 10 Hldgs %
33.01%
Holding
258
New
61
Increased
36
Reduced
52
Closed
65
Top Buys
| 1 |
Amazon
AMZN
|
$77.8M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$72M |
| 3 |
Biogen
BIIB
|
$48.7M |
| 4 |
PARA
Paramount Global Class B
PARA
|
$45.6M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$44.8M |
Top Sells
| 1 |
Madrigal Pharmaceuticals
MDGL
|
$298M |
| 2 |
Ross Stores
ROST
|
$114M |
| 3 |
Incyte
INCY
|
$76.6M |
| 4 |
Five Below
FIVE
|
$76.2M |
| 5 |
lululemon athletica
LULU
|
$74.2M |
Sector Composition
| 1 | Healthcare | 70.93% |
| 2 | Consumer Staples | 8.88% |
| 3 | Technology | 6.85% |
| 4 | Consumer Discretionary | 6.74% |
| 5 | Communication Services | 4.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $158M | 2.76% | 3,488,000 +1,588,000 | +84% | +$72M |
|
2
Supernus Pharmaceuticals
SUPN
$2.53B
| $155M | 2.71% | 4,356,000 -237,004 | -5% | -$8.45M |
|
3
Travere Therapeutics
TVTX
$1.56B
| $135M | 2.35% | 6,412,000 +576,000 | +10% | +$12.1M |
|
4
PTC Therapeutics
PTCT
$3.92B
| $130M | 2.26% | 3,396,000 +496,000 | +17% | +$18.9M |
|
|
5
Incyte
INCY
$16.5B
| $113M | 1.98% | 1,412,000 -954,000 | -40% | -$76.6M |
|
6
Freshpet
FRPT
$2.72B
| $113M | 1.97% | 2,136,000 -600,000 | -22% | -$31.7M |
|
|
7
Biogen
BIIB
$19.4B
| $111M | 1.93% | 400,000 +176,000 | +79% | +$48.7M |
|
8
Neurocrine Biosciences
NBIX
$13.8B
| $107M | 1.88% | 900,000 -424,000 | -32% | -$50.6M |
|
9
GSK
GSK
$79.9B
| $107M | 1.87% | 3,056,000 -544,000 | -15% | -$19.1M |
|
|
10
Amazon
AMZN
$2.44T
| $97.8M | 1.71% | 1,164,000 +926,500 | +390% | +$77.8M |
|
11
Enanta Pharmaceuticals
ENTA
$180M
| $96.7M | 1.69% | 2,078,000 +6,000 | +0.3% | +$279K |
|
|
12
Alphabet (Google) Class A
GOOGL
$2.57T
| $86.1M | 1.5% | 976,000 +508,000 | +109% | +$44.8M |
|
|
DCPH
13
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $84.8M | 1.48% | 5,172,000 +404,000 | +8% | +$6.62M |
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $79.4M | 1.38% | 110,000 -26,000 | -19% | -$18.8M |
|
15
Agios Pharmaceuticals
AGIO
$2.19B
| $77.2M | 1.35% | 2,750,000 +826,000 | +43% | +$23.2M |
|
16
Exact Sciences
EXAS
$8.98B
| $76M | 1.33% | 1,536,000 -24,000 | -2% | -$1.19M |
|
17
Alkermes
ALKS
$4.78B
| $75.8M | 1.32% | 2,900,000 -892,000 | -24% | -$23.3M |
|
18
Pacira BioSciences
PCRX
$1.2B
| $73.1M | 1.27% | 1,892,000 +300,000 | +19% | +$11.6M |
|
|
PARA
19
DELISTED
Paramount Global Class B
PARA
| $72.6M | 1.27% | 4,300,000 +2,700,000 | +169% | +$45.6M |
|
20
Organon & Co
OGN
$2.45B
| $67M | 1.17% | 2,400,000 +708,000 | +42% | +$19.8M |
|
21
argenx
ARGX
$43.6B
| $64.4M | 1.12% | 170,000 +50,000 | +42% | +$18.9M |
|
22
FibroGen
FGEN
$47.8M
| $61.9M | 1.08% | 3,864,000 -592,000 | -13% | -$9.48M |
|
|
23
Madrigal Pharmaceuticals
MDGL
$9.76B
| $60.4M | 1.05% | 208,000 -1,028,000 | -83% | -$298M |
|
24
Central Garden & Pet Class A
CENTA
$2.08B
| $54M | 0.94% | 1,509,000 -41,000 | -3% | -$1.47M |
|
25
Microsoft
MSFT
$3.77T
| $53.7M | 0.94% | 224,000 +63,000 | +39% | +$15.1M |
|